SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Monday, August 19, 2013

Part I: IPAB revokes Allergan's patent on eye drugs Ganfort and Combigan

Posted on 3:50 PM by Unknown
Crying their eyes out?
This two part post is about the recently revoked patents owned by Allergan Inc (USA). The patents covered the drugs Ganfort and Combigan, and were used in the treatment for Glaucoma. The drugs essentially reduced pressure in the eyes. The revocation applications were filed by Ajanta Pharma Ltd, a leading Indian drugmaker. Both applications applied for a revocation on  the grounds of obviousness and non-compliance of S. 8, and were successful on the same.  The Board consistently held that non-compliance of S. 8 will attract invalidation of the patent. The decisions were pronounced by Justice Sridevan (alongwith DPS Parmar) on her last day as the Chairman of the IPAB. Ajanta Pharma previously lost a trademark infringement suit to US drugmaker Alcon in 2008, in relation to similar brand-names of drugs used in treatment of Glaucoma. 


Patent I [ORA/20/2011/PT/KOL]

Ajanta Pharma Ltd filed a revocation application against Allergan's patented eye drug to cure Ocular Hypertension(Glaucoma). Allergan had claimed to achieve enhanced treatment of ocular hypertension with reduced side effects. The IPAB revoked the patent without costs. The invention was titled “Hypotensive Lipid (prostaglandin derivatives) and Timolol composition and methods of using same" [Patent No.212695] and, covered the drugs Ganfort and Combigan. The revocation application was filed on the grounds of non-compliance of s. 8 and obviousness of the invention. 

Applicants 

The applicants stated that the respondents had a duty to disclose information as per the requirements of s. 8 and the respondents did not disclose application numbers of the patent grant applications pending in various countries to the Indian Patent Office, despite providing undertakings for the same. 

The impugned patent was a fixed combination of Bimatoprost and Timolol. The only issue which the applicants focused on was whether the combination was obvious in view of simultaneous (five minute gap) administration of these known drugs referred to as serial or adjunct monothrapy. A number of citations were relied on but the obviousness argument principally rested on the previous combined fixed dose containing Latanoprost and Timolol, each disclosed by prior publication.    The counsel  submitted that the combination of Bimatoprost [US 5688819] and Timolol[US W09730710]  was obvious because it was only a matter of conventional and routine experimentation, to arrive at the claimed combination. The applicants stated that in absence of data that compares the claimed combination to combinations known in prior art, specifically, closest prior art combinations employing Timolol and a prostaglandin analog i.e. Latanoprost, there was no inventive merit or enhanced treatment that was exhibited.  In the present matter, it was obvious that a combination of a prostaglandin analog and a beta blocker, specifically Timolol, would result in an additive enhanced effect. This motivation with a reasonable expectation of success was sufficient to render the impugned patent obvious and devoid of inventive merit.

Respondents

Respondents contended that the revocation application was time barred because the patent had been granted in 2007, and the revocation application was filed only in 2011.

The respondents attempted to prove that the therapy was an unexpected result. According to the learned counsel the structural similarities between bimatoprost and latanoprost were overemphasized by the applicants.There were many chemical compounds that are as close structurally to latanoprost as bimatoprost is, and there is no reason why one of skill in the art would have considered bimatoprost alone as the best compound for modification of a latanoprost composition.

Decision

The IPAB held that the application was not time barred. The right to revoke patent any time after the grant of patent under section 64 cannot be extinguished by applying limitation of three years under Article 137 of the Limitation Act. This will run contrary to the scheme of the patent law and the application for revocation can be filed before Appellate Board any time after the grant of a patent.

The IPAB found that Latanoprost and Bimatoprost were analogs of Dinoprost.  Latanoprost, sold as Xalatan and Bimatoprost as Lumigan, both widely recognized in the treatment for glaucoma. Prior art taught use of Timolo and Latanoprost combination. . The Board categorically held that "We do not agree with the respondent that ‘no comparison was required as Latanoprost is different from Bimatoprost and a comparison of combinations comprising the two would be akin to comparing apples to oranges, as we find both are ‘oranges’ Bimatoprost [akin to seedless orange] better than latanprost [akin to orange with seeds] to lower the IOP."   The respondents may have been easily led to believe by prior art teachings that Bimatoprost like Latanoprost is capable of producing the same result if not better.  Therfore, the choice of Bimatoprost to replace Latanoprost was obvious use of a material generally available in the market and suitable for purpose. 

With respect to S. 8, yet again, the IPAB pointed out the unpleasant term 'settled' used in communication between the Controller and the respondents in respect of settling for submission of prosecution details of any one of the major Patent Offices internationally. The Board sincerely hoped that the practice dies a natural death. The Board held that in this case there was non compliance of S. 8(2) as no information relating to
prosecution of same application in other countries was provided even when the respondent agreed to do so as whenever it became available. "In the present case the ground of the violation of section 8 has been clearly made out and we have no hesitation say applicant succeeds on this ground of revocation"

The patent was revoked. No order was made regarding costs. 
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in Indian Pharma, obviousness, Patent, Patent act, Pharma, revocation, Section 3(d), section 8 | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • Call for Papers: IIT Bombay and MHRD jointly announce the 2nd International Conference on Management of Intellectual Property and Strategy
    The readers may be interested to know that the Shailesh J. Mehta School of Management of IIT Bombay is geared up to host, in collaboration w...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • Karnataka High Court temporarily restrains German company from exploiting trade secrets of Homag India
    Image from here In an interesting judgment dated 10th October, 2012 the Karnataka High Court, sitting at Bangalore, has passed an interim in...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ▼  August (41)
      • SpicyIP Tidbit: ALCS August Distribution
      • PIP Essay Competition Results Announced: Meet the ...
      • Now Showing: Satyagraha: Bom HC denies an Injuncti...
      • Patenting food: Plumpy’ Nut and more?
      • Bollywood flick Satyagraha faces dispute over its ...
      • Leading IP Academics Fired: Protest Petition Again...
      • Two MHRD IP Chair Professors axed; Reasons unknown
      • FICCI and The George Washington University, Washin...
      • SpicyIP Tidbit: IPA continues communication with P...
      • SpicyIP Tidbit: GI for Pedana Kalamkari Art Form
      • Colgate v Pepsodent: Comparative Advertising
      • SpicyIP Tidbit: Justice KN Basha to be new IPAB ch...
      • IPRS complies with new copyright law & decides to ...
      • Re-imposing curbs on royalty payments to foreigners
      • Debating the CIS Draft Bill on Privacy: Should thi...
      • The BDR compulsory licensing application and the B...
      • Satyajit Ray's sketches and copyright controversies
      • Rihanna's victory in the Topshop T-shirt case
      • When cancer drugs stop being “necessities”: A case...
      • SpicyIP Tidbit: Singers from the South in support ...
      • Loss of an IP Leader: RIP Prof Daruwalla
      • Part II: IPAB revokes Allergan's patent on eye dru...
      • Part I: IPAB revokes Allergan's patent on eye drug...
      • Feedback on draft guidelines for Computer Related ...
      • A naïve report from Parliament on FDI in the Pharm...
      • INTAvening in the Supreme Court: Parallel Imports ...
      • Surprising news! - Roche decides to not ‘pursue’ H...
      • Independent Intellectual Property: Gunning For (or...
      • SpicyIP Tidbit: Special Services announced by WIP...
      • GI News: Kaipad Rice, Nagpur Oranges, Dharmavaram ...
      • SpicyIP Tidbit: Patent Office confirms status of G...
      • The Sholay litigation saga
      • SpicyIP Tidbit: Has Genentech’s main Herceptin pat...
      • Bollywood flick 'I love NY' accused of plagiarisin...
      • The Herceptin patent fiasco at the Indian Patent O...
      • IPO vs IPAB: IT Prowess and Transparency?
      • Ghost Post: Samsung v. Apple Presidential Enforcem...
      • Delhi HC dismisses Rediff.com's Copyright Infringe...
      • UNICEF Supply Annual Report 2012 : India is the La...
      • Raj Anand Moot Court Competition 2013
      • Breaking News: GSK patents challenged: IPAB revoke...
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ►  April (51)
    • ►  March (66)
    • ►  February (40)
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.